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The cysteinyl leukotrienes (LTs),' LTC4, LTD4, and LTE4, are arachidonate me-
tabolites generated in the 5-lipoxygenase pathway (1-3) . Full activation of 5-lip-
oxygenase requires a Cat+ -dependent translocation of the enzyme from the cytosol
to a membrane-bound site (4-6). Inhibition of this process was shown to prevent
IT generation (6, 7) . LTC4, which is formed by conjugation of the 5-lipoxygenase
product LTA4 with glutathione, is rapidly metabolized within the vascular space by
the ectoenzymesy-glutamyltransferase and, inmost species, dipeptidase (8), yielding
LTD4 and LTE4, respectively (9-11) . LTC4, LTD4, and LTE4 are eliminated from
the blood circulation with initial half-lives of30-40 s (9, 10, 12-14), mainly taken
up by the liver and excreted into bile (9, 10, 12-17). A portion of the cysteinyl LTs
eliminated with bile undergoes enterohepatic circulation (9, 18).
Alimited number ofcell types, including mast cells, eosinophils, andmononuclear
phagocytes, are capable of producing LTC4 (2, 19-22), which is presumed to play
a majorrole as a mediator ofhypersensitivity reactions and inflammation (1-3, 23).
In guinea pigs, intravenously administered LTC4 or LTD4 provoke severe respira-
tory distress as well as the typical hemodynamic changes observed in systemic
anaphylaxis (23, 24) . Enhanced production in vivo of endogenous LTC4 was
demonstrated in acute anaphylaxis (16) and under several otherpathophysiological
conditions (25), including tissue trauma (12), endotoxin shock (17), shock induced
by staphylococcal enterotoxinB (9), hepatorenal syndrome (26), infusion ofTNFa
(27), and injection of platelet-activating factor (PAF) (10) .
A variety ofhumoral mediators, including the LTs (16, 28), histamine (29), PAF
(30), andprostanoids (31, 32), are involved in the pathogenesis ofsystemic anaphylaxis.
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Guinea pigs suffering from anaphylactic shock produce LTD4 endogenously in
amounts that may be sufficient to induce cardiovascular and hemodynamic effects
leading to severe shock reactions in this species (16). Therefore, inhibitors of IT
synthesis as well as IT receptor antagonists (33) may be of therapeutic value in the
treatment of anaphylactic shock. Since the antiinflammatory glucocorticosteroids
are potent antiasthmatic drugs, we set out to test the possibility that dexamethasone
prevents symptoms of systemic anaphylaxis in the guinea pig by inhibiting the re-
lease of Us in vivo. We demonstrate the suppression of cysteinyl IT generation in
vivo during anaphylactic shock by the novel IT biosynthesis inhibitor MK-886
(previous code number, L-663,536; chemical name, 3-[1-(4-chlorobenzyl)-3-i-butyl-
thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid) (7). In animals pretreated
with the histamine H1 receptor antagonist pyrilamine, inhibition of whole body
LTC4 generation is associated with a protection from death and other consequences
of acute systemic anaphylaxis.
Materials and Methods
Special Reagents.
￿
Unlabeled LTC4, LTD4, and LTE4 were purchased from Miles Scientific
through Bayer Diagnostik (Miinchen, FRG). [14,153H2]LTC4, [14,153H2]LTD4, and [14,15-
3H2]LTE4 (40 Ci/mmol or 1.5 x 10'5 Bq/mol, each) were obtained from New England Nu-
clear (Boston, MA). N-Acetyl-LTE4 and N-acetyl-[3H]LTE4 were synthesized from LTE4 and
[3H]LTE4, respectively, using acetic anhydride (15). Reversed-phase HPLC (RP-HPLC)
separation served to control the purity of the LTs and to purify the unlabeled LTs (9). The
concentration ofunlabeled LTs was determined by absorbancemeasurements at 280 nm using
an extinction coefficient of 40,000 cm-' x M-' (34). 6-Keto [5,8,9,11,12,14,15-H7] PGF,,,,, sp
act 157 Ci/mmol or 5.81 x 10'5 Bq/mol, and the 6-keto-PGF,c , assay system were from Amer-
sham Buchler (Braunschweig, FRG). 4-Hydroxy-2,2,6,6-tetramethylpiperidine-N(1)-oxyl
(HTMP), L-penicillamine, OVA (grade III), pyrilamine maleate, Evans' blue, methyl cellu-
lose, zymosan A, y-glutamyltransferase, and activated charcoal were obtained from Sigma
Chemical Co. (St. Louis, MO); dexamethasone 21-dihydrogenphosphate (Fortecortin) was
from E. Merck (Darmstadt, FRG); dextran T 70 (ti70 kD) from Pharmacia Fine Chemicals
(Uppsala, Sweden); ketamine (Ketavet) from Parke-Davis (Miinchen, FRG); and xylazine
(Rompun) from BayerLeverkusen (Leverkusen, FRG). PBS and Eagle's MEM were obtained
from BoehringerMannheim Biochemicals (Mannheim, FRG), and supplemented with L-glu-
tamine (2 mM), penicillin (100 U/ml), and streptomycin (100 mg/ml) (Gibco Laboratories,
Grand Island, NY). Dr. G. Neil, Upjohn Co. (Kalamazoo, MI), kindly supplied acivicin.
MK-886 (L-663,536) sodium salt, was a generous gift from Drs. J. Rokach and J. Gillard,
Merck Frosst Canada (Pointe-Claire/Dorval, Quebec, Canada). The monoclonal cysteinyl
IT antibody was kindly donated by Dr. F. Kohen, The Weizmann Institute ofScience (Re-
hovot, Israel).
AnimalExperiments.
￿
Male guinea pigs ofthe Hartley strain (Interfauna Siiddeutsche Ver-
suchstierfarm, Tuttlingen, FRG) weighing 400-600 g were actively sensitized to OVA 3 wk
before antigen challenge by intraperitoneal injection of 3 Rg/kg OVA mixed with 300 mg/kg
Al(OH)3 to produce both IgE- and IgGl-like antibodies (35). Cutaneous testing of the sen-
sitization was performed in each animal by examination ofthe local extravasation of intrave-
nously injected Evans blue dye (10 mg/kg, dissolved in saline) after intradermal injection
of OVA (1 leg). Sensitized guinea pigs were defined as those showing a blue area of at least
6 mm in diameter at the site of OVA injection. Animals were anesthetized with ketamine
(50 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). After a median laparotomy with an incision
length of 2 cm, the cystic duct was ligated, the gall bladder punctured, and the bile duct
cannuaated (polyethylene tubing, 1.0-mm outer diameter, 0.6-mm inner diameter; Dow
Corning Corp., Midland, MI) (16). The animal's core temperature was maintained at 37 t
1°C with a heating pad. After cannulation ofbothjugular veins and ofthe left carotid artery,GUHLMANN ET AL.
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the animals were kept under anesthesia for 3 h to avoid an interference of the LT measure-
ments by LTs generated during the trauma required for the surgical interventions (12).
Anaphylaxis was induced by intravenous administration of0.2 mg/kg OVA dissolved in sa-
line. For metabolic experiments, [3H2]LTC4 (5 ACi/kg) was either injected intravenously as
a bolus or infused into the jugular vein over a period of 15 min in sensitized animals exposed
to antigen challenge as well as in sensitized controls. Arterial blood was withdrawn into a
syringe containing PBS with 3 mM EDTA, 2 mM acivicin, 2 MM L-penicillamine, 1 mM
HTMP (final concentrations) at pH 7.4 (10). Blood samples were mixed immediately with
4 vol of ice-cold methanol containing 1 mM HTMP. Bile was collected continuously under
argon into ice-cold 90% (vol/vol) aqueous methanol, containing 1 mM HTMP and 0.5 mM
EDTA at pH 7.4.
Respiratory and Hemodynamic Parameters.
￿
A small polyethylene catheter (0.3-mm inner di-
ameter; Dow Corning) was passed via the left carotid artery into the aorta for pressure mea-
surements, monitoringof the heart rate (BioTach, Gould-Brush, Cleveland, OH), and blood
sampling. Two additional polyethylene catheters (0.6-mm inner diameter) were introduced
into both externaljugular veins for drug and anesthetic administration. Arterial blood gases
were analyzed by ABL 3 equipment (Radiometer, Copenhagen, Denmark). The animals were
tracheotomized and a metaltube (2.6-mm inner diameter) was inserted for artificial ventila-
tion (Animal Respirator Type 4600; Rhema Labortechnik, Hofheim, FRG) with an air/02
mixture (Fi02, 30%; arterial PC02, 4.7-5.3 kPa). No positive endexpiratory pressure was
used. Respiratory pressures were measured through the tube and by a 26-gauge needle in-
serted into the trachea 5 mm belowthe tube. All pressures were monitored via Statham P231D
pressure transducers calibrated manometrically before each experiment; the zero level was
set at midchest position. The cardiovascular and respiratory variables were simultaneously
recorded on a multi-channel polygraph (Mk 481; Brush, Cleveland, OH). The dynamic lung
compliance (Cdyn) was calculated as: tidal volume/(respiratory peak pressure - endexpira-
tory pressure).
DrugAdministration.
￿
The animals received the histamine antagonist pyrilaminemaleate,
dissolved in saline, at 1 mg/kg, i.v, 5 min before the immunologic challenge with OVA. Dexa-
methasone was administered either over a period o£ 7 d (10 mg/kg daily, i.p., the last dose
was given intravenously 1 h before the challenge with OVA) or at a single dose of 10 mg/kg
i.v, 3.5 h before immunological challenge. MK-886 was given at a dose of 1 or 10 mg/kg,
i.v, 15 min before OVA. MK-886 was first dissolved in absolute ethanol (200 mg/ml) and
then diluted with a 0.1% aqueous solution of methyl cellulose to 10 mg/ml. OVA challenge
controls received the vehicle alone. Unlabeled LTC4 was infused intravenously over a period
of 5 min in a total dose of 2 nmol/kg.
Guinea PigHritonealMacrophage Culture.
￿
Before the surgical manipulations described above,
resident peritoneal macrophages were isolated from dexamethasone-treated (10 mg/kg, i.p.,
once daily for 7 d) and from untreated sensitized guinea pigs by lavage with sterile PBS.
1-2 x 106 peritoneal macrophages were plated on 5-cm-diameter plastic tissue culture dishes
(Becton Dickinson & Co., Mountain View, CA) in 3 ml ofEagle's MEM containing 5% FCS
for 2 h at 37°C under 5% C02/95To air. After removal of nonadherent cellsby washing the
dishes twice with PBS, the adherent cells were placed in 2 ml of serum-free Eagle's MEM
containing 50 1&g/ml of unopsonized zymosan prepared by the method of Bonney et al. (36).
The cells were then cultured for 2 h at 37'C under 5% C02/95% air. The cell superna-
tants were removed and passed through Sep-Pak cartridges containing octadecylsilyl silica
(10 x 10 mm; Waters Associates, Milford, MA) that had been prewashed sequentially with
50 ml each ofmethanol, water, methanol/water (1 :9, vol/vol) containing 14 mM EDTA, pH
7.4, and water. After applying the samples, the columns were rinsed successively with 5 ml
of water, 15% (vol/vol) aqueous methanol, and benzene; LTs and PGs were then eluted with
2 ml of absolute methanol. Using this procedure, recoveries of 3H-labeled cysteinyl LTs and
of 3H-labeled 6-keto-PGF,a were at 85 t 5% and 82 t 3%, respectively. Aliquots o£ the
methanol fractions were dried under vacuum and arachidonate metabolites were analyzed
by RIA.
RPRHPLC
￿
For deproteinization before application to HPLC, biological samples were
made of 80% methanol containing 1 mM HTMP, stored at -30°C for at least 3 h, and1908
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centrifuged at 10,000 g for 10 min at 4oC. For analyses ofendogenous cysteinyl LTs, aliquots
of the supernatants equivalent to 25 141 of bile were mixed with 800 cpm each of [3H]LTC4,
[3H]LTD4, [3H]LTE4, and N-acetyl-[3H]LTE4 to correct for recovery losses in the analysis
ofendogenous LTs. The samples were dried in a SpeedVac concentrator (Savant Instruments,
Inc., Hicksville, NY) and resuspended in 30% (vol/vol) aqueous methanol. RP-HPLC was
performed isocratically on a C18-Hypersil column (4.6 x 250 mm, 5-,um particles; Shandon,
Runcorn, UK) with a C18 precolumn (Waters Associates). The mobile phase consisted of
65% (vol/vol) methanol in aqueous buffer (0.1% acetic acid, 1 mM EDTA, pH 5.6, adjusted
with ammonium hydroxide). The flow rate was 1 ml/min. For analyses of the [3H]LT me-
tabolite pattern in blood and bile, tritium in the HPLC eluent was detected continuously
with a liquid scintillation device (LB 505; Berthold, Wildbad, FRG) using a Rialuma scintil-
lation mixture from Baker Chemicals (Gross-Gerau, FRG). For analyses ofendogenous cys-
teinyl LTs, a 400-p,1 aliquot of each 1-ml fraction collected during HPLC was counted for
calculation of tritium recovery, and 600 pl was dried for the subsequent RIA. The amounts
ofimmunoreactive IT metabolites coeluting with the [3H]LT standards added to each sample
before HPLC were corrected for recovery losses and immunologic crossreactivity in the RIA.
RIAfor Cysteinyl LTs.
￿
The assay procedure is a modification of the one described previ-
ously (9). A 600-141 aliquot of the HPLC fractions, as well as evaporated aliquots of macro-
phage supernatants prepared as described above and resuspended in 600 JAI of HPLC eluate,
were evaporated to dryness and resuspended in 200 141 of assay buffer (0.9% NaCl, 0.1%
gelatin, 10 mM EDTA, 0.1% sodium azide in 10 mM phosphate buffer, pH 7.4). Tubes for
LTC4, LTD4, and LTE4 standard curves also contained 600141 of dried, LTfree HPLC eluate.
Antibody, diluted 1 :105 in assay buffer, was added to the samples and standards. After
mixing and a 30-min preincubation period at room temperature, [3H]LTE4 (6,000 cpm) was
added in 100 141 of assay buffer, mixed, and incubated at 4oC for 16-20 h. Unbound
[3H]LTE4 was removed by addition of 1 ml of ice-cold charcoal suspension (0.63% charcoal,
0.063% dextran in 10 mM phosphate buffer, pH 7.4) and, after 4 min, by centrifugation
at 1,400 g for 15 min at 4oC. The supernatant was added to 10 ml of scintillation fluid for
counting of radioactivity. The lower detection limit of the assay system for LTD4 was at -13
frnol. The molar crossreactivities at 50% binding of LTE4, N-acetyl-LTE4, LTD4, and LTC4
were 100, 140, 160, and 210%, respectively.
RIAfor 6-ketoprostaglandin Fl,.
￿
The assay system provided by Amersham Buchler was
used. The 6-keto-PGF,q antibody crossreacted with prostanoids as follows: 6-keto-PGFI.,
100%; PGE2, 5.1%; PGF2a, 0.30%; PGD2, <0.014%; thromboxane B2, <0.014% (relative
molar crossreactivities at 50% binding). The lower detection limit for 6-keto-PGF,~ was at
-40 fmol.
EnzymaticModification ofEndogenously Formed L7U4.
￿
Deproteinized bile collected 0-15 min
after OVA challenge was mixed with 800 cpm of [3H]LTC4 as standard, evaporated to dry-
ness, resuspended in 30% (vol/vol) aqueous methanol, and fractionated by RP-HPLC. Frac-
tions coeluting with [3H]LTC4 were evaporated to dryness, dissolved in PBS (pH 7.0) con-
taining .y-glutamyltransferase (50 mU/ml) and L-penicillamine (2 mM) (10), and incubated
for 30 min at 37°C. After deproteinization in 80% (vol/vol) aqueous methanol and centrifu-
gation, the supernatants were evaporatedto dryness, redissolved in 30% (vol/vol) methanol,
and subjected to RP-HPLC . Fractions were analyzed for LTD4 by RIA as described above.
Statistical Analyses.
￿
Data from different experiments were combined and reported as the
mean t SEM. Student's two-tailed t test was used to analyze differences for significance.
Normal distribution was ascertained and the Bonferroni correction was applied. Significant
differences in the lethality studies (Table II) were calculated using Woolf's G test.
Results
Elimination and Metabolism of Labeled L71;'4 after its Intravenous Injection or Infu-
sion. [3H]LTC4, injected intravenously as a bolus, underwent rapid elimination
from the circulating blood with an initial half-life of the radioactivity of 38 t 4 s.
Extensive conversion of [3H]LTC4 to [3H]LTD4 occurred within the vascular space(Fig. 1). 68 t 3% of the radioactivity in arterial blood coeluted with standard
[3H]LTD4 as analyzed by RP-HPLC of samples collected 2 min after intravenous
injection of [3HJLTC4. Only a slow conversion to [3H]LTE4 wasobserved in the cir-
culation. The initial half-life of ['H]LTC4 itself was 15 s in the vascular bed ofthe
guinea pig and resulted from both hepatobiliary elimination and conversion to
[3HJLTD4.
Thehepatobiliary elimination ofcysteinyl LTs and the biliarymetabolite pattern
were analyzed afterintravenous infusion of[3H]LTC4 over a 15-min period. Within
30 min, 67 t 6% ofthe infused radioactivity was recovered inbile (Fig. 2). HPLC
analyses indicated that [3H]LTD4 and [3HJLTC4 represented the major metabolites
in bileamountingto 46 t 1% and 18 t 4%, respectively, ofthe infused dose within
30 min. Only small amounts of tracer corresponded to biliary [3H]LTE4 and
[3H]LT metabolites more polar than [3H]LTC4. Intravenous infusion of[3H]LTC4,
together with unlabeled LTC4 (2 nmol/kg), showed a similar biliary metabolite
profile. In these animals LTC4 caused a 37% (n = 4; p < 0.005) decrease in bile
flow during a 15-min period after infusion. No significant differences in either the
biliaryexcretion rate orin the biliary IT metabolite pattern were observed between
sensitized animals exposed to antigen challenge and sensitized controls.
In.fluence of LT Biosynthesis Inhibition on Systemic LTC4 Generation In Vivo during
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FIGURE 1.
￿
Distribution of cysteinyl Us in the blood circulation after
intravenous injection of[3H]LTC4 (5 uCi/kg) as a bolus. Blood samples
were collected and immediately mixed with a cold solution containing
EDTA, acivicin, and L-penicillamine as described in Materials and
Methods. Acivicin and L-penicillamine served to inhibit-y-glutamyltrans-
ferase and LTD4 dipeptidase, respectively, and thereby prevent further
catabolism of LTC4 and LTD4 (10). [3H]LTs in blood were separated by
RP-HPLC and expressed asrelative percentages. Mean values from three
guinea pigs t SD are given.
FIGURE 2.
￿
['HILT metabolites accumulated in bile during
and after intravenous infusion over 15 min of[14,15-3H2]LTC4.
Biliary ['HILT metabolites were separated by RP-HPLC and
defined by their retention times and coelution with [3HILT
~ 40 standards. The amount ofthe metabolites accumulated in bile
is expressed as percent of the infused dose. LT,1 designates
W [3H]LT metabolites more polar than [3H]LTC4; E LT repre-
+LTC, J sents totalradioactive LT metabolites excreted into bile. Mean 0 20
values from four animals t SEM are given.
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Anaphylaxis.
￿
Biliarycysteinyl Us were analyzed during anaphylactic shock, induced
by intravenousinjection ofOVA(0.2 mg/kg) into sensitized guinea pigs, by the com-
bined use of RP-HPLC andsubsequent RIA. Aradioimmunochromatogram ofbile
samples collected before and after OVA challenge is shown in Fig. 3. In accordance
with previous studies (16), LTD4 was the major endogenous immunoreactive LTC4
metabolite in anaphylactic guinea pig bile. Antigen challenge was followed by a 30-
fold increase in the biliary LTD4 concentration from 2.1 t 0.6 nmol/liter bile to
63 t 7 nmol/liter (n = 10) (Fig. 4). In line with thetracer studies(Fig. 2), an addi-
tional endogenous metabolite coeluting with LTC4 was observed (Fig. 3). Biliary
LTC4 levels increased from 1.2 t 0.9 nmol/liter bile to 33 t 11 nmol/liter after
OVA challenge. The identity of the LTC4 was confirmed by enzymatic conversion
by ,)-glutamyltransferase to LTD4 followed by rechromatography and radioimmuno-
logic analysis. [3H]LTC4, added as an internal standard, was also completely con-
verted to [3H]LTD4. The bile flow decreased from 115 t 5 IAI x min-1 x kg-1 in
prechallenge fractions to 85 t 4 IA1 x min-1 x kg-1 (n = 10; p < 0.05) in post-
challenge fractions collected 0-15 min after OVA. Based on the total recovery of
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FIGURE 3.
￿
Effect of theIT biosynthesis inhibitorMK-886
on antigen-induced cysteinylIT generation in vivo. Biliary
cysteinyl LTs were separated by RP-HPLC and fractions
were analyzed by RIA as described in Materials and
Methods. Arrows indicate retention times of internal
[3H]LT standards added to each sample before HPLC in
smallamountsnotinterfering with the RIA. (Lowerpanels)
Radioimmunochromatograms ofbile samples collected 30-0
minbefore antigen challenge. (Upperpanel, left)Analysis of
bile sample collected 0-15 min afterOVAchallenge. (Upper
panel, right) Suppression ofantigen-induced rise in cysteinyl
IT concentrationin the postchallengesample ofguinea pig
pretreated with the IT biosynthesis inhibitor MK-886 (10
mg/kg, i.v.) 15 min before challenge.
FIGURE 4.
￿
Time course of LTD4 levels in bile from OVA-
challenged, pyrilamine-pretreated guinea pigs with or
without pretreatment with the IT biosynthesis inhibitor
MK-886 or dexamethasone. Theinhibitorwasgivenintra-
venously 15 min before challenge at the indicated doses;
dexamethasone was administered intraperitoneally over a
period of 7 d(10 mg/kgdaily). Systemic LTC4 production
was followed by measurement of the LTD4 concentration
in bile samplescollected during 30 minbefore andduring
severaltime intervals after antigen challenge. Each LTD4
valuewasdetermined by RP-HPLC andsubsequent RIA
as in Fig. 3, andis presentedas themean t SEM. In chal-
lengecontrols and in dexamethasone-treatedguinea pigs,
thenumber ofanimals, shownnext to thesymbols, decreased
with time due to early death.
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LTC4 (75 t 5%) and LTD4 (71 t 3%), and on the finding that within 30 min,
46 and 18% of the infused [3H]LTC4 were recovered from bile as [3H]LTD4 and
[3H]LTC4, respectively (Fig. 2), the total amount of LTC4 produced during
anaphylaxis within a 30-min period wascalculated to be 0.8 t 0.2 nmol/kg (n = 10).
The IT biosynthesis inhibitor MK-886, at a dose of 10 mg/kg, blocked the rise
of the LTD4 concentration in bile (Figs. 3 and 4) as well as of the LTD4 production
rate (Table I) by >92% (p < 0.001) within the 30-min period after OVA challenge.
MK-886 also prevented the anaphylaxis-induced decrease in bile flow observed in
the OVA challenge controls. Pretreatment with a lower dose of MK-886 (1 mg/kg,
i.v, 15 minbefore challenge) resulted in asignificant reduction(,4< 0.001)ofbiliary
LTD4 as compared with OVA challenge controls in samples collected 0-15 min after
antigen challenge (Fig. 4). However, no significant decrease in LTD4 levels in bile
was observed at later time periods. At both inhibitor doses most of the pyrilamine-
pretreated guinea pigs were protected from earlydeath caused by the OVA-induced
anaphylactic shock (Fig. 4; Table II). Moreover, symptoms usually following the
OVA challenge, such as acute respiratory distress, cyanosis, and micturation, were
abolished by the pretreatment with MK-886.
InfluenceofDexamethasoneon EicosanoidProduction.
￿
Pretreatment ofguinea pigs with
dexamethasone (10 mg/kg, iv ., 3.5 hbefore OVA challenge) did not inhibitthe antigen-
induced cysteinyl IT production (Table I). Moreover, long-term administration of
high dexamethasone doses (10 mg/kg, i.p., once daily for 7 d) did not suppress the
anaphylaxis-induced LTC4 production in vivo as measured by the LTD4 concen-
tration in bile (Fig. 4). To further investigate the action of the steroid on eicosanoid
release, we isolated resident peritoneal macrophages from sensitized guinea pigs
pretreated with dexamethasone in vivo for 7 d (10 mg/kg daily, i.p.). Macrophages
harvested from untreated sensitized guinea pigs served as controls. Exposure to
zymosan was followed by a 36-fold increase in LTC4 production and by a 13-fold
increase in 6-keto-PGF1q release (Table III). Dexamethasone pretreatment in vivo
induced an 88% inhibition of LTC4 generation as well as a 61% suppression of 6-
TABLE I
Influence of Dexamethasone and of the LT Biosynthesis Inhibitor MK-886
on the LTD4 Production Rate during Anaphylactic Shock
The LTD4 production rate was calculated from the biliary LTD4 concentra-
tionandfrom bile flow during the time periods before andafter antigen challenge
as indicated. Values are means t SEM. The number of animals (given in
parentheses) decreased with time in the challenge controls dueto early death.
Dexamethasone wasgiven at asingle dose of 10 mg/kg, i.v., 3 .5 h before OVA
challenge.
: MK-886 was administered at a doseof 10 mg/kg, i.v., 15 minbefore challenge.
S Statistically significant as compared with OVA challenge controls (p < 0.001).
Time interval Control Dexamethasone' MK-886:
min pmol LTD¢ x min-' x kg-1
-30-0 0.3 t 0.1 (10) 0.6 t 0.2 (5) 0.2 t 0.1 (4)
0-15 6.2 t 1 .8 (10) 6.4 t 2.9 (5) 0.3 t 0.1 (4)S
15-30 5 .2 t 1 .5 (6) 3.3 t 1.3 (5) 0.6 t 0.3 (4)S
30-90 1 .8 t 0.8 (6) 1 .4 t 0.5 (5) 0.5 t 0.2 (4)1912
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TABLE II
Effect of Inhibitors on Anaphylactic Death in Sensitized Guinea Pigs
Lethality caused by systemic anaphylaxis was recorded up to 2 h after in-
travenous injection ofOVA (0.2 mg/kg) into sensitized guinea pigs. All animals
were anesthetized as described in Materials and Methods.
' The histamine Ht antagonist pyrilamine maleate was given intravenously at
a dose of 1 mg/kg 5 min before OVA challenge.
1 Statistically different from group without treatment before OVA challenge by
p < 0.05 (Woolf's G test).
S The IT biosynthesis inhibitor MK-886 was administered intravenously 15 min
before challenge.
II Dexamethasone was given intraperitoneally to sensitized guinea pigs over a
period of 7 d (10 mg/kg daily).
keto-PGF1a release in zymosan-stimulated macrophages (Table III). RIAs after RP-
HPLC separation indicated that -60% of the immunoreactive cysteinyl LTs released
by the macrophages corresponded to LTC4, whereas LTD4 and LTE4 amounted to
-20% each.
Respiratory andHemodynamic Parameters undertheInfluenceofEicosanoid Synthesis Inhtbi-
tors during SystemicAnaphylaxis. Guinea pigs, pyrilamine pretreated, artificially ven-
tilated, and challenged with OVA, showed a 56% decrease (p < 0.05) in the Cdy
TABLE III
Effect of Dexamethasone on Eicosanoid Production by
Stimulated Peritoneal Macrophages
Resident peritoneal macrophages were isolated from dexamethasone-treated
sensitized as well as from untreated sensitized guinea pigs. 2-h adherent peri-
toneal macrophage cultures were incubated with zymosan, and arachidonate
metabolites were analyzed by RIA as described in Materials and Methods.
Values shown for cysteinyl LTs are LTC4 pmol equivalents. All values are
means t SEM. The number of experiments is given in parentheses.
Zymosan was added to macrophage cultures at 50 jug/ml.
Dexamethasone was given i.p. to sensitized guinea pigs over a period of 7 d
(10 mg/kg daily).
Statistically significant as compared with zymosan-stimulated macrophages
harvested from untreated sensitized guinea pigs (p < 0.001).
Treatment before OVA challenge Lethality
Number of
guinea pigs
0 /0
None 100 8
Pyrilamine* 78 9
MK-886 (10 mg/kg)S 601 10
Pyrilamine* + MK-886 (I mg/kg)S 251 8
Pyrilamine* + MK-886 (10 mg/kg)S 01 10
Pyrilamine* + dexamethasonell 331 6
Treatment Cysteinyl LTs 6-keto-PGFI~
pmol/106 cells
None 2.3 t 0.3 (4) 8.4 t 1 .5 (4)
Zymosan' 82 .5 t 5 .4 (4) 105 .7 t 9.8 (4)
Dexamethasonet + zymosan' 9 .5 t 3.5 (6)S 40.8 t 7.4 (6)S0
i
E u
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a
J
a
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FIGURE 5.
￿
Dynamiclung compliance in OVA-challenged,
pyrilamine-pretreated guineapigs with or without pretreat-
ment with the LT biosynthesis inhibitor MK-886 or dexa-
methasone, as well as in sensitized guinea pigs afterLTC4
infusion. The inhibitor was given intravenously in a dose
of 10 mg/kg 15 min before theantigen was injected at t =
0;dexamethasone wasadministered intraperitoneally over
a period of 7 d (10 mg/kg daily). Cdrn was measured and
calculated as described in Materials and Methods. LTC4
(2 nmol/kg) was infused over 5 min into four animals. The
experimental groups challenged with OVA were composed
of five animals each. Mean values t SEM are given.
(Fig. 5). The Cdyn was significantly improved (p < 0.05) by additional pretreatment
of the animals with the LT biosynthesis inhibitor MK-886 (10 mg/kg). Dexametha-
sone (10 mg/kg, i.p., once daily for 7 d) did not prevent the early OVA-induced de-
crease in Cdyn, but after60 min, Cdyn was normalized (Fig. 5). The infusion of LTC4
(2 nmol/kg) into sensitized guinea pigs caused a 47% decrease in Cdyn (p < 0.05),
corresponding to the above-mentioned decrease in the challenged control animals.
After OVA challenge the hematocrit increased in all animals within 60 min (p <
0.05). This rise wasmost pronounced in the challenge control group(+53%). MK-
886, but not dexamethasone, significantly suppressed (p < 0.05) the increase in he-
matocrit. The infusion of LTC4 caused a 25% increase in hematocrit within 60 min
(p <0.05). In OVA-challenged controls, the mean arterial pressure (MAP) decreased
from 56 t 4 (prechallenge value) to 25 t 4 mm Hg within 30 min after challenge
(p < 0.05). No significant changes in either MAP or in theheart rate were observed
in dexamethasone- or MK-886-pretreated animals 30 min afterOVA challenge. In-
fusion of LTC4 into sensitized guinea pigs caused a decrease in MAP from 54 t
1 (prechallenge value) to 39 t 3 mm Hg within 30 min (p < 0.05), as well as a
15% decrease in heart rate.
Discussion
This study was aimed at an inhibition of systemic cysteinyl IT production in vivo.
Moreover, it was of interest whether the suppression of IT generation could reduce
thelife-threatening manifestations ofsystemic anaphylaxis. Recently, an animal model
has been developed that enables measurements of systemic LTC4 formation during
anaphylactic shock in the guinea pig (16). We have used this model to evaluate in
vivo the efficacy of dexamethasone and of the novel and potent inhibitor of 5-lip-
oxygenase activation and IT biosynthesis MK-886 (7). This inhibitor is selective
for the 5-lipoxygenase pathwayof arachidonate metabolism as demonstrated by the
lack of effect on 12-lipoxygenase, 15-lipoxygenase, or cyclooxygenase (7).
As thebasis for measurements ofthe systemic production ofendogenous cysteinyl1914
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Us, [3H]LTC4 served as the precursor for determination of the metabolite pattern
of Us in blood and bile. In the guinea pig, elimination of intravenously injected
[3H]LTC4 from the blood circulation was as fast as in the monkey (9, 11) and in
the rat (10, 12-14). LTC4 was rapidlyconverted within the vascular space to the most
biologically potent cysteinyl IT, LTD4, which was rather slowly metabolized to
LTE4 (Fig. 1). This is in contrast to LTC4 metabolism in the monkey and the rat,
where LTE4 is the predominant metabolite in circulating blood as early as 1 min
after intravenous injection of LTC4 (9-11). Thelimited degradation of LTD4 to LTE4
within the vascular space in the guinea pig may be related to the high sensitivity
of this species to cysteinyl Us (24). Only 1 nmol/kg of intravenous LTC4 or LTD4
evoked widespread plasma extravasation (37). Cysteinyl LT-induced plasma extrava-
sation around bile ducts, as indicatedby means of Evans blue (37), maybe respon-
sible for the significant decrease in bile flow that we observed in sensitized guinea
pigs after infusion of LTC4, as well as during anaphylactic shock.
Antigen provocation of OVA-sensitized guinea pigs was associated with a large
increase in the biliary excretion of LTD4 (16) and, to a lesser extent, of LTC4 under
our conditions (Fig. 3). Calculation of the systemic LTC4 production in vivo was
based on the predominanthepatobiliaryelimination andthe biliary metabolite pat-
tern after intravenous infusion of labeled LTC4 over a 15-min period (Fig. 2). The
infusion served to mimic the time course of endogenous LTC4 production during
anaphylaxis (Fig. 4, Table I). It should be noted that the guinea pigs, under our
experimental and feeding conditions, showed a minimal capacity for m oxidation
of LTE4, thus forming only small amounts of biologically inactive, polar IT me-
tabolites (Fig. 2). In adifferent environment (16), polar LTE4 metabolites can com-
prise a larger fraction .
The antigen-induced LTC4 production was fully suppressed after pretreatment
with the IT biosynthesis inhibitor MK-886 (Figs. 3 and4, TableI). This compound
does not modify the hepatobiliary elimination of cysteinyl Us (7). Prevention of
the anaphylactic LTC4 production protected the pyrilamine-pretreated animals
against lethal shock(Fig. 4; TableII), andsignificantlyreduced theantigen-induced
decrease in Cdyn (Fig. 5), as well as the rise in hematocrit. Moreover, infusion of
LTC4 or LTD4 into guinea pigs caused changes in Cdyn (23), mean systemic arterial
pressure (23), and hematocrit (37) similar to those observed during anaphylactic
shock (Fig. 5). This indicates that LTs play an important role in this model of
anaphylaxis.
Pretreatment with dexamethasone at various doses did not inhibit the antigen-
induced cysteinyl IT production in vivo (Fig. 4, Table I). However, dexamethasone
pretreatment in vivo induceda strong inhibition ofcysteinylIT generation in zymosan-
stimulated resident peritoneal macrophages (Table III). These findings indicate that
the glucocorticosteroid was active in the guinea pigmacrophagesbutnot in thecells
responsible for the anaphylactic LTC4 release in vivo. In the model of anaphylaxis
used in the present investigation (35), mast cells are likely to be the main source
of endogenous LTC4. The lack of effect of dexamethasone on anaphylactic LTC4
generation in vivo (Fig. 4, Table I) is in line with previous studies demonstrating
that purifiedhumanmast cells areinsensitive to the inhibitory action of dexametha-
sone when stimulated with anti-IgE to release LTC4 (22). Moreover, systemic glu-GUHLMANN ET AL.
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cocorticoid treatment had neither an effect on the release of LTC4 and LTB4, nor
on the symptoms during the early-phase nasal allergic reaction after allergen chal-
lenge in humans (38, 39). A novel additional activity of glucocorticosteroids was
describedrecently (40), showing thatdexamethasone isa potent suppressor ofmast
cellsensitization induced byIgE antibodyinamodeloftype I allergic inflammation
in vivo. Accordingly, dexamethasone may inhibit IgE fixation to mast cells during
thesensitization period, thuspreventing mediator release that is inducedbybridging
of the receptor-bound IgE antibodies by antigen.
We did observe, however, some protection ofdexamethasone-treated guinea pigs
during systemic anaphylaxis as evidenced by normalization ofthe Cdy,, value 60 min
after OVA challenge (Fig. 5). This may be related to the inhibitory action ofdexa-
methasoneonthe release ofsecondary mediators (41). Cysteinyl Us areable totrigger
the release ofthromboxane A2 (42, 43) and PAF (44). The LTC4-induced release
ofthromboxane A2 can be inhibited in guinea pig perfused isolated lungs by recom-
binant human lipocortin 1 (43). Our measurements demonstrate for the first time
that dexamethasone does not act in guinea pig anaphylaxis by a suppression of
LTC4 generation. Protection against lethal anaphylactic shock has been accom-
plished, on the other hand, by blocking the systemic production of LTC4 with an
inhibitor of 5-lipoxygenase activation.
Summary
Leukotriene C4 (LTC4) underwent rapid elimination from the circulating blood
and was extensively converted to LTD4 within the vascular space ofthe guinea pig.
To mimic the elimination and metabolism of endogenous LTC4 generated during
anaphylaxis, 14,15-3H-labeled LTC4 was infused intravenously over a period of 15
min, leading to a recoveryin bileof85% ofthe infused IT radioactivity within 2 h.
Corresponding to the tracer studies, LTD4 and, to a lesser extent, LTC4 were the
predominant endogenous cysteinyl Us in guinea pig bile. The biliary production
rate of endogenous LTD4 increased from 0.3 t 0.1 to 6.2 t 1.8 pmol x min-1
x kg-' (p < 0.001) during anaphylactic shock induced by intravenous injection of
OVA(0.2 mg/kg) into sensitized guinea pigs. Anovel ITbiosynthesis inhibitor(MK-
886; 10 mg/kg, iv, 15 minbefore antigen challenge)suppressed the antigen-induced
cysteinyl IT production by >92% (p < 0.001). This inhibition ofsystemic LTC4 for-
mation was associated with acomplete protection against lethal anaphylactic shock
in animals pretreated in addition with the H1 receptor antagonist pyrilamine.
Pretreatment witheither the inhibitor ofIT synthesis or the histamine receptor an-
tagonist reduced the lethality during anaphylactic shock from 100 to 60 and 78%,
respectively. In artificially ventilated, pyrilamine-pretreated animals, the antigen-
induced decrease in dynamic lung compliance and the rise in hematocrit were
significantly reduced (p < 0.05) by pretreatment with the inhibitor ofIT synthesis.
Dexamethasone at high doses (10 mg/kg, i.p., once daily for 7 d, or in a single dose
of 10 mg/kg, i.v., 3.5 h before challenge) had no inhibitory effect on IT generation
during anaphylaxisin vivo. However, inresident peritoneal macrophages, harvested
from these dexamethasone-treated sensitized guinea pigsand stimulatedwith zymosan,
both cysteinyl IT and 6-keto-PGFI« formation were strongly suppressed. These
studies indicate an important role ofcysteinyl Us in systemic anaphylaxis in vivo1916
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and demonstrate the blockade of anaphylactic LT generation by a novel inhibitor
of IT biosynthesis (MK-886) but not by dexamethasone.
We thank Dr. Michael Huber for helpful discussions and support. Dedicated to Prof. Karl
Decker on the occasion of his 65th birthday.
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